Dechra Pharmaceuticals Share Price

DPH

GB0009633180

Delayed London S.E. Other stock markets 01:00:00 16/01/2024 pm IST			5-day change	1st Jan Change
3,866.00 ^GBX	-.--%		-.--%	-

25/06	Dechra Opens New Global Headquarters in Boston and Invests $60,000 in Local Community Partnerships	CI
19/05	Dechra Veterinary Products LLC Announces FDA Approval Of Cosacthen Cosyntropin Injection For Canine Patients	CI

Valuation: Dechra Pharmaceuticals

Market Cap	440.36Cr 587.52Cr 516.02Cr 479.89Cr 827.4Cr 57TCr 840.16Cr 5.7TCr 2.23TCr 28TCr 2.21TCr 2.16TCr 96TCr	P/E 2022	64.8x	P/E 2023	-150x
Enterprise Value	483.37Cr 644.91Cr 566.42Cr 526.76Cr 908.22Cr 62TCr 922.22Cr 6.26TCr 2.44TCr 31TCr 2.42TCr 2.37TCr 1,05600Cr	EV / Sales 2022	5.8x	EV / Sales 2023	6.08x
Free-Float	-	Yield 2022	1.3%	Yield 2023	0.34%

* Estimated data More valuation ratios

Latest news : Dechra Pharmaceuticals

25/06	Dechra Opens New Global Headquarters in Boston and Invests $60,000 in Local Community Partnerships	CI
19/05	Dechra Veterinary Products LLC Announces FDA Approval Of Cosacthen Cosyntropin Injection For Canine Patients	CI
31/03	Dechra Pharmaceuticals Limited Announces Termination of Jonathan David Lang as Director, Effective March 31, 2026	CI
11/03	Dechra Announces Consolidation Of Its Existing U.S. Office Footprint In Kansas City, Kan. And Portland, Maine	CI
11/03	Dechra Announces Plans to Relocate Its Global Headquarters from Northwich, England, to Boston, Massachusetts	CI
13/25/13	Intervacc Extends Equine Strangles Vaccine Distribution Deal with Dechra Pharmaceuticals	MT
13/25/13	Intervacc and Dechra Extend Distribution Agreement for Intervacc's Equine Strangle Vaccine Strangvac by Two Years	CI
03/25/03	Dechra Pharmaceuticals Limited completed the acquisition of Invetx, Inc. from a group of shareholders for approximately $530 million	CI
18/25/18	Dechra Pharmaceuticals PLC Launches Strangvac in Spain, Portugal and Slovenia	CI
17/25/17	Vaxxinova GmbH acquired Poultry Vaccines Business of Dechra Pharmaceuticals Limited.	CI
05/25/05	Dechra Pharmaceuticals to Launch Intervacc's Horse Vaccine in Finland	MT
05/25/05	Dechra Pharmaceuticals plc Launches Strangvac in Finland	CI
18/24/18	Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.	CI

More news

Analysts' recommendations: Dechra Pharmaceuticals

27/23/27	Stifel Downgrades Dechra Pharmaceuticals to Hold from Buy, Lowers PT	MT
27/23/27	Analyst recommendations: Alphabet, Amgen, GSK, Moderna, Smiths Group...
27/23/27	UBS cuts BT'; HSBC starts Smiths with 'hold'	AN
07/23/07	Davy ups Purplebricks; JPMorgan cuts Clarkson	AN
12/23/12	UBS cuts Beazley; Berenberg likes Rio and BHP	AN

More recommendations

Press Releases: Dechra Pharmaceuticals

27/23/27	Form 8.5 (EPT/RI) - Dechra Pharmaceuticals plc	AQ
30/23/30	Dechra Pharmaceuticals : 30 October 2023 Annual Report 2023 (Online)	PU
17/23/17	Dechra Pharmaceuticals : 17 October 2023 Annual Report 2023 ESEF XHTML	PU
17/23/17	Dechra Pharmaceuticals : 17 October 2023 Annual Report 2023	PU
07/23/07	Form 8.3 - Dechra Pharmaceuticals plc	AQ

More press releases

News in other languages: Dechra Pharmaceuticals

12/24/12	BOLETÍN MATINAL : 12 de enero de 2024
13/23/13	Pharma und Gesundheit: weitere Konsolidierung
13/23/13	Farma en gezondheid: consolidatie gaat door
11/23/11	Farmaceutica e salute: continua il consolidamento
11/23/11	Farmacia y salud: La consolidación continúa

More news

Managers and Directors: Dechra Pharmaceuticals

Manager	Title	Age	Since
Jesper Nordengaard CEO	Chief Executive Officer	-	10/06/2024
Paul Sandland DFI	Director of Finance/CFO	46	03/04/2019
Jamie Adams CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Paul Sandland BRD	Director/Board Member	46	30/10/2019
Lawson Macartney BRD	Director/Board Member	68	01/12/2016
Lisa Bright BRD	Director/Board Member	59	01/02/2019

More insiders

Dechra Pharmaceuticals PLC specializes in the manufacturing and marketing of veterinary pharmaceutical products. Net sales break down by family of products as follows: - companion animal products (74.6%); - food producing animal products (11.5%); - equine health products (7.3%); - animal feeds (5.1%); - other (1.5%): products manufactured by third parties. Net sales are distributed geographically as follows: the United Kingdom (8.5%), Germany (9.2%), Europe (31.2%), the United States (37.9%) and other (13.2%).

Employees

Sector

More about the company

3 years	3,644	3,868
5 years	2,473.32	5,525
10 years	1,225	5,525

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/01/24	Ian Page	Free	Chief Executive Officer	18,551	0.0163%
15/01/24	Paul Sandland	Buy	Chief Financial Officer	227	0.0002%
15/01/24	Ian Page	Free	Chief Executive Officer	3,580	0.0031%

	2022	2023
Net sales	68Cr 91Cr 80Cr 74Cr 128.1Cr 8.76TCr 130.08Cr 882.29Cr 344.7Cr 4.31TCr 341.48Cr 334.12Cr 15TCr	76Cr 101.6Cr 89Cr 83Cr 143.08Cr 9.78TCr 145.29Cr 985.43Cr 385Cr 4.81TCr 381.4Cr 373.18Cr 17TCr
Net income	5.82Cr 7.76Cr 6.82Cr 6.34Cr 11Cr 747.78Cr 11Cr 75Cr 29Cr 367.63Cr 29Cr 29Cr 1.27TCr	-2.79Cr -3.72Cr -3.27Cr -3.04Cr -5.24Cr -358.47Cr -5.32Cr -36Cr -14Cr -176.24Cr -14Cr -14Cr -609.34Cr
Net Debt	21Cr 28Cr 24Cr 23Cr 39Cr 2.68TCr 40Cr 269.42Cr 105.26Cr 1.32TCr 104.28Cr 102.03Cr 4.55TCr	43Cr 57Cr 50Cr 47Cr 81Cr 5.53TCr 82Cr 556.58Cr 217.45Cr 2.72TCr 215.42Cr 210.77Cr 9.39TCr

Dechra Pharmaceuticals Share Price

Stocks

DPH

GB0009633180

Valuation: Dechra Pharmaceuticals

Latest news : Dechra Pharmaceuticals

Analysts' recommendations: Dechra Pharmaceuticals

Press Releases: Dechra Pharmaceuticals

News in other languages: Dechra Pharmaceuticals

Course Extremes

Managers and Directors: Dechra Pharmaceuticals

Latest insider transactions

Financials

Company Profile